Drug Combinations for the Treatment of Duchenne Muscular Dystrophy

A combination comprising an ancillary agent and a compound of Formula (I) or (II):

• wherein
• A1, A2, A3, A4 and A5, which may be the same or different, each represent N or CR1;
• R9 represents -L-R3, in which L is a single bond or a linker group and R3 represents hydrogen or a substituent;
• when an adjacent pair of A1-A4 each represent CR1, the adjacent carbon atoms, together with their substituents, may form a ring B;
• and
• when A5 represents CR1 in formula (I), A5 and N—R9, together with their substituents, may form a ring C;
• or a pharmaceutically acceptable salt thereof.